BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Chen, Dong ^a   Huang, Jun Fu ^a   Liu, Kai ^a   Zhang, Li Qun ^a   Yang, Zhao ^a   Chuai, Zheng Ran ^a   Wang, Yun Xia ^a   Shi, Da Chuan ^a   Huang, Qing ^a   Fu, Wei Ling ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PROTEIN MLH1; BRAF PROTEIN, HUMAN;

AGE; ALCOHOL CONSUMPTION; ARTICLE; BRAF GENE; CANCER LOCALIZATION; CANCER STAGING; COLORECTAL CANCER; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HISTOPATHOLOGY; HUMAN; MICROSATELLITE INSTABILITY; MUTATION RATE; ONCOGENE K RAS; PROTEIN METHYLATION; SEX DIFFERENCE; SYSTEMATIC REVIEW; TUMOR DIFFERENTIATION; COLORECTAL TUMOR; GENETIC MARKER; GENETICS; META ANALYSIS; MISSENSE MUTATION; PATHOLOGY; REVIEW; RISK;

COLORECTAL NEOPLASMS; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; HUMANS; MUTATION, MISSENSE; ODDS RATIO; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84897012482     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090607     Document Type: Article

References (41)

1. Weitz J, Koch M, Debus J, Höhler T, Galle PR, et al. (2005) Colorectal cancer. Lancet 365: 153-165. (Pubitemid 40091806)
2. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, et al. (2011) Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117: 4623-4632.
3. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, et al. (2008) Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122: 2255-2259. (Pubitemid 351542328)
4. Rose JS, Serna DS, Martin LK, Li XB, Weatherby LM, et al. (2012) Influence of KRAS Mutation Status in Metachronous and Synchronous Metastatic Colorectal Adenocarcinoma. Cancer 118: 6243-6252.
5. Markowitz SD, Bertagnolli MM (2009) Molecular Basis of Colorectal Cancer. N Engl J Med 361: 2449-2460.
6. Vilkin A, Niv Y, Nagasaka T, Morgenstern S, Levi Z, et al. (2009) Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel. Cancer 115: 760-769.
7. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532.
8. Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260: 816-819. (Pubitemid 23167612)
9. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, et al. (2008) Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 14: 3408-3415.
10. Issa JP (2004) CpG island methylator phenotype in cancer. Nat Rev Cancer 4: 988-993.
11. Sclafani F, Gullo G, Sheahan K, Crown J (2013) BRAF mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumour phenotypes and clinical implications. Crit Rev Oncol Hematol 87: 55-68.
12. Krol LC, t Hart NA, Methorst N, Knol AJ, Prinsen C, et al. (2012) Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma. Eur J Cancer 48: 1108-1115.
13. Phipps AI, Buchanan DD, Makar KW, Burnett-Hartman AN, Coghill AE, et al. (2012) BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev 21: 1792-1798.
14. Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, et al. (2008) Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26: 4217-4219.
15. Bagadi SB, Sanghvi M, Nair SB, Das BR (2012) Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. Int J Biol Markers 27: 27-33.
16. Bozzao C, Varvara D, Piglionica M, Bagnulo R, Forte G, et al. (2012) Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients. Int J Biol Markers 27: e366-e374.
17. Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale(NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed 23 August 2012.
18. Mao C, Huang Y-F, Yang Z-Y, Zheng D-Y, Chen J-Z, et al. (2013) KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer. Cancer 119: 714-721.
19. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, et al. (2005) Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65: 6063-6069.
20. Rako I, Jakic-Razumovic J, Katalinic D, Sertic J, Plestina S (2012) Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients. Neoplasma 59: 376-383.
21. Shaukat A, Arain M, Thaygarajan B, Bond JH, Sawhney M (2010) Is BRAF mutation associated with interval colorectal cancers? Dig Dis Sci 55: 2352-2356.
22. Rozek LS, Herron CM, Greenson JK, Moreno V, Capella G, et al. (2010) Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev 19: 838-843.
23. Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, et al. (2011) Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation. Int J Cancer 128: 2075-2084.
24. Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, et al. (2011) Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol 29: 2675-2682.
25. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, et al. (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466-474.
26. Kadiyska TK, Konstantinova DV, Atanasov VR, Kremensky IM, Mitev VI (2007) Frequency and application of the hot spot BRAF gene mutation (p.V600E) in the diagnostic strategy for Hereditary Nonpolyposis Colorectal Cancer. Cancer Detect Prev 31: 254-256. (Pubitemid 47248148)
27. Naguib A, Mitrou PN, Gay LJ, Cooke JC, Luben RN, et al. (2010) Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. BMC cancer 10.
28. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, et al. (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104: 856-862.
29. Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, et al. (2010) Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 15: 390-404.
30. Marzouk O, Schofield J (2011) Review of histopathological and molecular prognostic features in colorectal cancer. Cancers 3: 2767-2810.
31. Ang PW, Li WQ, Soong R, Iacopetta B (2009) BRAF mutation is associated with the CpG island methylator phenotype in colorectal cancer from young patients. Cancer Lett 273: 221-224.
32. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A (2010) Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 127: 367-380.
33. Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, et al. (2012) BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: An aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 36: 744-752.
34. Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, et al. (2003) BRAF Mutations in Colon Cancer Are Not Likely Attributable to Defective DNA Mismatch Repair. Cancer Res 63: 5209-5212. (Pubitemid 37139829)
35. English DR, Young JP, Simpson JA, Jenkins MA, Southey MC, et al. (2008) Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev 17: 1774-1780.
36. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, et al. (2006) BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 5.
37. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, et al. (2010) The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 21: 2396-2402.
38. Li HT, Lu YY, An YX, Wang X, Zhao QC (2011) KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep 25: 1691-1697.
39. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, et al. (2012) Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 18: 890-900.
40. Curtin K, Samowitz WS, Wolff RK, Herrick J, Caan BJ, et al. (2009) Somatic alterations, metabolizing genes and smoking in rectal cancer. Int J Cancer 125: 158-164.
41. Samowitz WS, Albertsen H, Sweeney C, Herrick J, Caan BJ, et al. (2006) Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 98: 1731-1738. (Pubitemid 44942711)